<DOC>
	<DOCNO>NCT00628251</DOCNO>
	<brief_summary>The purpose study compare efficacy safety 2 dos drug AZD2281 liposomal doxorubicin see effective well tolerate treat patient measurable BRCA1- BRCA2-positive advanced ovarian cancer fail previous platinum therapy .</brief_summary>
	<brief_title>Dose-finding Study Comparing Efficacy Safety PARP Inhibitor Against Doxil BRCA+ve Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Advanced ovarian cancer positive BRCA1 BRCA2 status Progressive recurrent disease platinumbased chemotherapy Measurable disease RECIST Previous anthracycline treatment Brain metastases Less 28 day since last treatment use treat disease Considered poor medical risk due serious uncontrolled disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced ovarian cancer</keyword>
	<keyword>BRCA1 protein</keyword>
	<keyword>BRCA2 protein</keyword>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
</DOC>